EVE Health Group Limited (AU:EVE) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
EVE Health Group reports a 17% increase in Meluka Australia’s revenue for the September quarter, driven by the re-launch of its probiotic powder supplement and the introduction of the Gut Starter range. The company also completed the sale of its Robyndale tea tree property, strengthening its financial position and enabling exploration of strategic acquisitions. EVE Health Group continues to focus on expanding its market presence with ongoing product innovation and potential acquisitions.
For further insights into AU:EVE stock, check out TipRanks’ Stock Analysis page.